# **Special Issue**

# Photothermal Therapy: Efficiency and Future Directions

## Message from the Guest Editor

Light-activated, photosensitizer-based therapies have been established as safe modalities for the treatment of various diseases, such as Alzheimer's disease, dermatological disease and tumor ablation for numerous indications. Photothermal therapy, which results in localized thermal damage, is one of the main approaches available. There are still many challenges to enhance the efficiency and efficacy of this treatment approach. It is our great pleasure to invite you to submit a paper to *Molecules*.

## **Guest Editor**

Prof. Dr. Jin Zhou College of Pharmacy, Weifang Medical University, Weifang, China

## Deadline for manuscript submissions

closed (31 December 2022)



## **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/117458

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules





## **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

#### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

## **Journal Rank:**

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

